Indications
Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.
Composition
- Active substance
- insulin aspart, insulin degludec
- International name (INN)
- insulin degludec;insulin aspart
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ryzodeg
- Active substance
- insulin aspart, insulin degludec
- ATC code
- A10AD06
- Therapeutic area
- Diabetes Mellitus
- Marketing authorisation holder
- Novo Nordisk A/S
- Status
- Authorised